KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+6.1%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$289M
AUM Growth
+$289M
(-16%)
Cap. Flow
-$68.2M
Cap. Flow
% of AUM
-23.62%
Top 10 Holdings %
Top 10 Hldgs %
99.7%
Holding
12
New
–
Increased
8
Reduced
4
Closed
–
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$236K |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$199K |
| 3 |
Biogen
BIIB
|
$140K |
| 4 |
McKesson
MCK
|
$128K |
| 5 |
Alkermes
ALKS
|
$124K |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$54.6M |
| 2 |
United Therapeutics
UTHR
|
$12.2M |
| 3 |
AnaptysBio
ANAB
|
$1.83M |
| 4 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
$443K |
Sector Composition
| 1 | Healthcare | 97.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enanta Pharmaceuticals
ENTA
$180M
| $42.6M | 14.73% | 862,848 +4,037 | +0.5% | +$199K |
|
|
2
United Therapeutics
UTHR
$13.8B
| $41.7M | 14.44% | 249,421 -73,116 | -23% | -$12.2M |
|
|
TARO
3
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $40.4M | 13.98% | 547,639 -6,007 | -1% | -$443K |
|
|
4
Regeneron Pharmaceuticals
REGN
$61.5B
| $39.1M | 13.54% | 82,698 +498 | +0.6% | +$236K |
|
|
5
Biogen
BIIB
$19.4B
| $38.8M | 13.41% | 138,518 +501 | +0.4% | +$140K |
|
|
6
McKesson
MCK
$85.4B
| $32.7M | 11.32% | 167,640 +657 | +0.4% | +$128K |
|
|
7
Alkermes
ALKS
$4.78B
| $30.4M | 10.52% | 1,627,323 +6,648 | +0.4% | +$124K |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $14.1M | 4.87% | 6,449,408 +26,000 | +0.4% | +$56.7K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $7.28M | 2.52% | 908,236 +3,689 | +0.4% | +$29.6K |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $1.06M | 0.37% | 6,912 -357,362 | -98% | -$54.6M |
|
|
11
AnaptysBio
ANAB
$569M
| $554K | 0.19% | 25,690 -84,758 | -77% | -$1.83M |
|
12
NextCure
NXTC
$13.5M
| $306K | 0.11% | 30,603 +311 | +1% | +$3.11K |
|